Perdagangan Vir Biotechnology VIR

Jual
 Beli

VirBiotechnology diagram langsung

5m 15m 30m 1h 4h 1d 1w

Dasar-dasar Instrumen

Weekly Search
Weekly
Daily
Tanggal Tutup Ubah Ubah (%) Buka Tinggi Rendah

VirBiotechnology news

Berita Terkini

Tampilkan lebih banyak
Noah Lee 2025 Sep 12, 10:20

US-Japan Joint Statement: Reaffirming Market-Driven Exchange Rates

Emma Rose 2025 Sep 12, 09:20

Goldman Sachs, UBS Raise Gold Price Forecasts for 2025

Noah Lee 2025 Sep 12, 09:20

Albania Appoints AI Minister to Combat Corruption in Public Procurement

Emma Rose 2025 Sep 11, 15:20

Dalio: Gold as a Hedge Against Mounting Debt Risks

Ava Grace 2025 Sep 11, 14:20

Switzerland Proposes US Gold Refinery to Reduce Tariffs

Noah Lee 2025 Sep 11, 14:20

NATO and EU on Edge After Russian Drone Enters Poland: A Critical Test

Liam James 2025 Sep 11, 10:20

Economists Anticipate BOJ Rate Hike in Q4 Amidst Global Uncertainties

Sophia Claire 2025 Sep 11, 10:20

Fed Rate Cut Debate Intensifies: Employment Data Revision Fuels Calls for Action

Info

Spread

0.05

Spread (%)

0.9615 %

Leverage

1:10

Bunga Overnight Beli

-0.0597 %

Bunga Overnight Jual

-0.0292 %

Mata Uang

USD

Jam Trading

Pasar tutup

Jumat

13:31 - 19:59

Senin

13:31-19:59

Selasa

13:31-19:59

Rabu

13:31-19:59

Kamis

13:31-19:59

Analisis dan Statistik

Buka

---

Sebelumnya Tutup

---

52 Minggu Tigg/Rdh

--- – ---

Kapitalisasi Pasar

712639104

Saham yang Beredar

138916000

Tanggal Penghasilan (Berikutnya)

0000-00-00

Hasil Div

Tanggal Non-Dividen

Proyeksi tingkat dividen tahunan

0

Proyeksi hasil dividen tahunan

0

EPS

-4.01

Pelajari lebih lanjut tentang instrumen ini

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). It has grant agreements with Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

Instrumen Terkait

Aset
Jual
Beli
Ubah (%)

Lakukan Trading

Lakukan Trading

Lakukan Trading

Lakukan Trading
view_all_instruments

latest_education_articles

Tampilkan lebih banyak
Trustpilot